Compare MTN & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | KTTA |
|---|---|---|
| Founded | 1997 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.3M |
| IPO Year | 1997 | 2021 |
| Metric | MTN | KTTA |
|---|---|---|
| Price | $142.66 | $1.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 1 |
| Target Price | ★ $174.18 | $3.00 |
| AVG Volume (30 Days) | 1.0M | ★ 21.4M |
| Earning Date | 12-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 7.24 | N/A |
| Revenue | ★ $2,975,101,000.00 | N/A |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $3.36 | N/A |
| P/E Ratio | $20.36 | ★ N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $129.85 | $0.28 |
| 52 Week High | $191.85 | $3.85 |
| Indicator | MTN | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 60.02 |
| Support Level | $140.00 | $1.02 |
| Resistance Level | $163.34 | $1.21 |
| Average True Range (ATR) | 5.56 | 0.10 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 12.92 | 51.88 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).